Evaluation of Physicians' Knowledge and Attitudes Towards Biosimilars in Russia and Issues Associated with Their Prescribing.

The most important factors for deciding to use biosimilars by specialty were: for hematologists, comparative clinical trials (86%; p = 0.002); for rheumatologists, comparative immunogenicity data (59%; p = 0.027); and for oncologists, cost of treatment (46%; p = 0.048; marginally significant). 3.5.

also in 26,082 other papers